Loading clinical trials...
Loading clinical trials...
A Multi-Center, Double-Phase, Randomized, Double-Blind, Placebo Controlled (12-Week Double-Blind Followed by 12-Week Open-Label) Study Evaluating the Effect of Tolterodine ER on Urgency Urinary Incontinence (UUI), Urgency, Frequency, Sexual Quality of Life and Sexual Function in Women With Overactive Bladder
Conditions
Interventions
Tolterodine ER 4mg QD
Locations
58
United States
Pfizer Investigational Site
Chandler, Arizona, United States
Pfizer Investigational Site
Phoenix, Arizona, United States
Pfizer Investigational Site
Little Rock, Arkansas, United States
Pfizer Investigational Site
Berkeley, California, United States
Pfizer Investigational Site
Oakland, California, United States
Pfizer Investigational Site
San Diego, California, United States
Start Date
March 1, 2005
Primary Completion Date
June 1, 2006
Last Updated
January 27, 2021
NCT05362292
NCT07105150
NCT01953263
NCT06411158
NCT06706362
NCT05806164
Lead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions